CoChat

Rivastigmine for vascular cognitive impairment

Open access
Birks, Jacqueline, McGuinness, Bernadette, Craig, David · 2013 · Cochrane Database of Systematic Reviews
Cited by 108

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Vascular dementia represents the second most common type of dementia after Alzheimer's disease. In older patients, in particular, the combination of vascular dementia and Alzheimer's disease is common, and is referred to as mixed dementia. The classification of vascular dementia broadly follows three clinico-pathological processes: multi-infarct dementia, single strategic infarct dementia and subcortical dementia. Not all victims fulfil strict criteria for dementia and may be significantly cognitively impaired without memory loss, when the term vascular cognitive impairment (VCI) is more useful. Currently, no established standard treatment for VCI exists. Reductions in acetylcholine and acetyltransferase activity are common to both Alzheimer's disease and VCI, raising the possibility that cholinesterase inhibitors - such as rivastigmine - which are beneficial in Alzheimer's disease, may also be beneficial for VCI. OBJECTIVES: To assess the efficacy of rivastigmine compared with placebo in the treatment of people with vascular cognitive impairment (VCI), vascular dementia or mixed dementia. SEARCH METHODS: We searched ALOIS (the Cochrane Dementia and Cognitive Improvement Group's Specialized Register) on 12 February 2013 using the terms: rivastigmine, exelon, "SDZ ENA 713". ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases (The Cochrane Library, MEDLINE, EMBASE, CINAHL, PsycINFO, LILACS), numerous trial registries and grey literature sources. SELECTION CRITERIA: All unconfounded randomized double-blind trials comparing rivastigmine with placebo in the treatment of people with VCI, vascular dementia or mixed dementia were eligible for inclusion. DATA COLLECTION AND ANALYSIS: Two reviewers extracted and assessed data independently, and agreement was reached after discussion. They noted results concerning adverse effects. MAIN RESULTS: Three trials, with a total of 800 participants, were identified for inclusion. The participants in one trial did not have dementia, while the other two studies included participants with dementia of different severities. The dose of rivastigmine was different in each study. No pooling of study results was attempted because of these differences between the studies.One trial included 40 participants with subcortical vascular dementia (age range 40 to 90 years) with a mean mini-mental state examination (MMSE) score of 13.0 and 13.4 in the rivastigmine and placebo arms, respectively. Treatment over 26 weeks was limited to 3 mg rivastigmine twice daily, or placebo. No significant difference was found on any outcome measure relevant to cognition, neuropsychiatric symptoms, function or global rating, or in the number of withdrawals before the end of treatment.Another trial included 710 participants with vascular dementia, including subcortical and cortical forms (age range 50 to 85 years). Over 24 weeks, a mean dose of rivastigmine of 9.4 mg/day was achieved versus placebo. Baseline MMSE was identical for both groups, at 19.1. Statistically significant advantage in cognitive response (but not with global impression of change or non-cognitive measures) was seen with rivastigmine treatment at 24 weeks (MMSE change from baseline MD 0.6, 95% CI 0.11 to 1.09, P value 0.02; Vascular Dementia Assessment Scale (VaDAS) change from baseline MD -1.3, 95% CI-2.62 to 0.02, P value 0.05 ). Significantly higher rates of vomiting, nausea, diarrhoea and anorexia and withdrawals from treatment were noted in the participants randomized to rivastigmine compared with placebo (withdrawals rivastigmine 90/365, placebo 48/345, OR 2.02, 95% CI 1.38 to 2.98) (withdrawals due to an adverse event rivastigmine 49/365, placebo 19/345, OR 2.66, 95% CI 1.53 to 4.62, P value 0.0005).The third study included 50 participants (age range 48 to 84 years) with mean MMSE scores of 23.7 and 23.9 in the rivastigmine and placebo arms, respectively. Over a 24-week period, participants labelled as having cognitive impairment but no dementia (CIND) following ischaemic stroke were given up to 4.5 mg rivastigmine twice daily, or placebo. Primary and secondary outcome measures showed no statistically significant difference when considering neurocognitive abilities, function, neuropsychiatric symptoms and global performance. One participant in the rivastigmine group and two in the placebo group discontinued their medication because of an adverse effect. AUTHORS' CONCLUSIONS: There is some evidence of benefit of rivastigmine in VCI from trial data from three studies. However, this conclusion is based on one large study. Rivastigmine is capable of inducing side effects that lead to withdrawal in a significant proportion of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd004744.pub3

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 29

  1. Mok, 2007, Rivastigmine in Chinese patients with subcortical vascular dementia, Neuropsychiatric Disease and Treatment, 3, 943
  2. Black, 2011, Vascular cognitive impairment: epidemiology, subtypes, diagnosis and management, The journal of the Royal College of Physicians of Edinburgh, 41, 49, 10.4997/JRCPE.2011.121 · DOI
  3. Bruandet, 2009, Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease, Journal of Neurology, Neurosurgery, and Psychiatry, 80, 133, 10.1136/jnnp.2007.137851 · DOI · Paper page
  4. Bullock, 2004, Cholinesterase inhibitors and vascular dementia: another string to their bow?, CNS Drugs, 18, 79, 10.2165/00023210-200418020-00002 · DOI
  5. Chiu, 1994, The reliability and validity of the Cantonese version of Mini-Mental State Examination, East Asian Archives of Psychiatry: Official Journal of the Hong Kong College of Psychiatrists, 4 (Supp 2), 25
  6. D'elia, 1996, Colour Trails Test
  7. Erkinjuntti, 2000, Research criteria for subcortical vascular dementia in clinical trials, Journal of Neural Transmission, 59, 23
  8. Ferris, 1999, Cognitive outcome measures, Alzheimer Disease and Associated Disorders, 13 Suppl 3, S140
  9. Folstein, 1975, 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
  10. Galasko, 1997, An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study, Alzheimer Disease and Associated Disorders, 11 Suppl 2, S33, 10.1097/00002093-199700112-00005 · DOI · Paper page
  11. Hansen, 2008, Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis, Clinical Interventions in Aging, 3, 211
  12. Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]
  13. Kerola, 2010, The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly?, International Journal of Cardiology, 150, 123, 10.1016/j.ijcard.2010.10.018 · DOI
  14. Leung, 2001, Validation study of the Chinese version of the neuropsychiatric inventory (CNPI), International Journal of Geriatric Psychiatry, 16, 789, 10.1002/gps.427 · DOI
  15. Malouf, 2004, Donepezil for vascular cognitive impairment, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004395.pub2 · DOI · Paper page
  16. Manos, 1994, The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients, International Journal of Psychiatry in Medicine, 24, 229, 10.2190/5A0F-936P-VG8N-0F5R · DOI · Paper page
  17. Mok, 2004, The validity and reliability of chinese frontal assessment battery in evaluating executive dysfunction among Chinese patients with small subcortical infarct, Alzheimer Disease and Associated Disorders, 18, 68, 10.1097/01.wad.0000126617.54783.7 · DOI
  18. Morris, 1993, The Clinical Dementia Rating (CDR): current version and scoring rules, Neurology, 43, 2412, 10.1212/WNL.43.11.2412-a · DOI · Paper page
  19. O'Brien, 2000, The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms, Annals of the New York Academy of Sciences, 903, 482, 10.1111/j.1749-6632.2000.tb06403.x · DOI · Paper page
  20. Perry, 1997, Some developments in brain ageing and dementia, British Journal of Biomedical Science, 54, 201
  21. Pohjasvaara, 2003, Clinical features of MRI-defined subcortical vascular disease, Alzheimer Disease and Associated Disorders, 17, 236, 10.1097/00002093-200310000-00007 · DOI
  22. Reisberg, 1982, The Global Deterioration Scale for assessment of primary degenerative dementia, The American Journal of Psychiatry, 139, 1136, 10.1176/ajp.139.9.1136 · DOI · Paper page
  23. Rosen, 1984, A new rating scale for Alzheimer's disease, The American Journal of Psychiatry, 141, 1356, 10.1176/ajp.141.11.1356 · DOI · Paper page
  24. Schneider, 1997, Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study, Alzheimer Disease and Associated Disorders, 11 Suppl 2, S22, 10.1097/00002093-199700112-00004 · DOI · Paper page
  25. Toghi, 1996, Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarcts types as compared with Alzheimer-type dementia, Journal of Neural Transmission, 103, 1211, 10.1007/BF01271206 · DOI · Paper page
  26. Tong, 2002, The Validation of the Hong Kong Chinese Version of the Lawton Instrumental Activities of Daily Living Scale for institutionalized elderly persons., Occupation, Participation and Health, 22, 132, 10.1177/153944920202200402 · DOI · Paper page
  27. World Health Organization, 1992, The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Description and Diagnostic Guidelines
  28. Yesavage, 1982, Development and validation of a geriatric depression screening scale: a preliminary report, Journal of Psychiatric Research, 17, 37, 10.1016/0022-3956(82)90033-4 · DOI · Paper page
  29. Craig, 2004, Rivastigmine for vascular cognitive impairment 10.1002/14651858.CD004744.pub2, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004744.pub2 · DOI · Paper page

Cited by

See all 108

Metadata

Authors
Birks, J., McGuinness, B., & Craig, D.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2013-05-31
Volume
2013
Issue
5
Pages
CD004744-CD004744
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1553319073
Cited by
108
References
10
FWCI
6.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rivastigmine for vascular cognitive impairment. https://app.cochat.ai/papers/10.1002/14651858.cd004744.pub3
The paper
Birks, J., McGuinness, B., & Craig, D. (2013). Rivastigmine for vascular cognitive impairment. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004744.pub3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.